Brazilian biotechnology companies are increasingly contributing to neurodegenerative disease research and therapy development. With a growing academic ecosystem, particularly in São Paulo, Rio de Janeiro, and Minas Gerais, Brazil has emerged as a regional hub for neuroscience research in Latin America. Several Brazilian biotech companies and academic spin-outs are developing treatments for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions["@brazilian2024"].
The burden of neurodegenerative diseases in Brazil is substantial. Recent epidemiological studies estimate that approximately 1.8 million people in Brazil are living with dementia, with Alzheimer's disease representing approximately 60-70% of these cases. Parkinson's disease affects approximately 200,000-250,000 Brazilians, with prevalence expected to increase significantly as the population ages["@grimmer2024"]. The growing awareness of these conditions, combined with expanding clinical research infrastructure, has created opportunities for Brazilian biotech companies to address significant unmet medical needs.
This page covers Brazilian biotech companies focused on neurodegeneration, their therapeutic approaches, research collaborations, and development status. The Brazilian neurodegenerative disease biotech landscape represents an emerging but rapidly developing sector with unique strengths in stem cell therapy, natural product discovery, and clinical trial execution.
The company's neurodegeneration strategy focuses on targeting key inflammatory mediators in the Alzheimer's disease brain. Their lead program targets the NLRP3 inflammasome, a key driver of neuroinflammation that has been implicated in Alzheimer's disease progression. Preclinical studies in mouse models have demonstrated that anti-NLRP3 antibodies can reduce microglial activation and improve cognitive performance in APP/PS1 transgenic mice[@menezes2024].
Recepta has established collaborations with the University of São Paulo's Department of Neurology and the Brazilian Brain Institute to support its neuroscience programs. The company has received funding from FAPESP (São Paulo Research Foundation) through its Innovative Research in Small Business program to support its neurodegeneration pipeline development.
IBN's neurodegeneration research program spans multiple therapeutic modalities, with particular emphasis on stem cell therapy and neurotrophic factor approaches. The institute's stem cell research focuses on mesenchymal stem cells (MSCs) derived from adipose tissue and bone marrow, evaluating their potential for neuroprotection and immunomodulation in Alzheimer's and Parkinson's disease models[@shinomoto2023].
In Parkinson's disease, IBN researchers have conducted preclinical studies demonstrating that MSC transplantation can protect dopaminergic neurons in the substantia nigra and improve motor function in 6-hydroxydopamine lesioned rats. The institute has also explored the use of neurotrophic factors including GDNF and BDNF to support neuron survival and function.
IBN has established partnerships with several international research institutions and has participated in multicenter clinical trials for neurodegenerative diseases. The institute's clinical translation program aims to advance promising cell-based therapies from preclinical development to clinical testing.
The company's natural product screening program has identified several promising leads from Brazilian flora. Research conducted in collaboration with the University of Campinas has characterized neuroprotective properties of extracts from species including Handroanthus impetiginosus (Brazilian purple trumpet tree) and Baccharis dracunculus. These extracts have demonstrated antioxidant, anti-inflammatory, and anti-amyloid activities in in vitro assays.
Herbarium's drug discovery approach combines traditional ethnobotanical knowledge with modern pharmaceutical science. The company's team of natural product chemists works closely with neuroscientists to bioassay-guided fractionate active extracts and identify individual compounds responsible for neuroprotective effects. This approach has yielded several natural product scaffolds that are now being optimized through medicinal chemistry programs.
The company's neurodegeneration portfolio includes both nutraceutical and pharmaceutical candidates. The nutraceutical division markets brain health supplements containing standardized botanical extracts, while the pharmaceutical division advances lead compounds through preclinical development toward clinical trials.
The company's lead product is a cryopreserved MSC formulation designated CPX-001. In preclinical studies, CPX-001 demonstrated neuroprotective effects in models of both Alzheimer's disease and Parkinson's disease. In Alzheimer's models, MSC treatment reduced amyloid plaque burden and improved cognitive performance. In Parkinson's models, the cells protected dopaminergic neurons and improved motor function.
Cryopraxis has completed Phase 1 clinical trials evaluating CPX-001 in patients with Parkinson's disease. The study, conducted at several Brazilian clinical sites, demonstrated the safety and tolerability of intrathecal MSC administration. A Phase 2 trial in patients with early-stage Parkinson's disease is planned to begin in 2025, evaluating both safety and preliminary efficacy endpoints.
The company has established partnerships with international pharmaceutical companies for both funding and commercialization rights. These partnerships provide Cryopraxis with access to global markets and additional expertise in clinical development and regulatory affairs.
Brazil represents an important region for Astellas's global clinical development program. The country's large patient population, well-established neurology centers, and regulatory pathways through ANVISA (Brazilian Health Regulatory Agency) enable efficient trial execution. Astellas has conducted trials for its pipeline of Alzheimer's disease modulators and Parkinson's disease treatments in Brazilian patient populations.
While not a company per se, this consortium merits mention as a key organization advancing neurodegenerative disease research in Brazil. LANDRn coordinates multi-center clinical studies across Latin America, including Brazil, Argentina, Chile, and Colombia. The network has established standardized protocols for patient assessment and biomarker collection, enabling cross-border collaboration and data sharing[@barroso2023].
Brazil's academic research institutions form the foundation of the country's neurodegenerative disease research ecosystem. These institutions both generate new knowledge and provide trained researchers for the biotech sector.
The University of São Paulo's Department of Neurology represents Brazil's leading center for neurodegenerative disease research. Faculty members conduct research across Alzheimer's disease, Parkinson's disease, and related disorders, with particular strength in biomarker development and clinical characterization.
Research Areas:
The Federal University of Rio de Janeiro's Institute of Neuroscience (INC) conducts fundamental and translational research on neurodegenerative diseases. The institute's research programs emphasize neuroprotection and neuroplasticity mechanisms.
Research Focus:
The Federal University of Minas Gerais in Belo Horizonte has developed a strong clinical research program in neurodegenerative diseases, with particular emphasis on cognitive disorders and movement disorders.
Research Areas:
Brazilian companies and academic institutions are actively developing stem cell-based approaches for neurodegenerative diseases. This therapeutic modality offers potential for both neuroprotection and cell replacement strategies[@shinomoto2023].
Mesenchymal Stem Cells (MSCs):
MSCs represent the most advanced stem cell therapy approach in Brazil. Companies including Cryopraxis and the Brazilian Brain Institute have developed MSC-based products for neurological disorders. The mechanisms of action include:
Induced Pluripotent Stem Cells (iPSCs):
Several Brazilian research groups have established iPSC programs for disease modeling and drug screening. iPSCs derived from patients with familial Alzheimer's or Parkinson's disease enable study of disease mechanisms in relevant cell types and screening of therapeutic compounds.
Brazil's exceptional biodiversity provides unique opportunities for drug discovery in neurodegeneration[@martins2024]. The country's flora includes over 55,000 documented species, many of which have been used in traditional medicine and represent potential sources of neuroprotective compounds.
Amazonian Plants:
The Amazon rainforest contains numerous plant species with documented or suspected neuroactive properties. Research programs have identified:
Traditional Medicine Integration:
Brazilian researchers are working to integrate traditional knowledge from indigenous communities with modern drug development approaches. This includes documentation of traditional uses, scientific validation of bioactivity, and development of standardized botanical products.
Brazilian researchers are contributing to biomarker development for neurodegenerative diseases, with efforts focused on both validation of established biomarkers and discovery of novel markers[@silva2023].
CSF Biomarkers:
Studies at USP and other institutions have validated CSF Aβ42, total tau, and phosphorylated tau as diagnostic biomarkers in Brazilian populations. These studies have characterized the performance of these markers in the context of local clinical practice and healthcare infrastructure.
Blood-Based Biomarkers:
Emerging blood-based biomarker technologies are being evaluated in Brazilian cohorts. Plasma p-tau217, p-tau181, and neurofilament light chain (NfL) assays are being validated for use in clinical settings with limited access to CSF testing.
Genetic Biomarkers:
Research on genetic risk factors in Brazilian populations has identified both known risk variants and novel associations specific to admixed Latin American populations.
Gene therapy represents an emerging therapeutic approach in Brazil, with several groups and companies developing programs targeting neurodegenerative diseases[@duarte2024].
AAV Vectors:
Brazilian researchers have established capabilities in adeno-associated virus (AAV) vector development for CNS gene delivery. Research programs are exploring AAV-mediated expression of neurotrophic factors including GDNF and BDNF for Parkinson's disease.
Gene Editing:
CRISPR-based gene editing approaches are being developed for both gain-of-function and loss-of-function mutations in familial neurodegenerative disease. These programs aim to develop precision therapies for patients with specific genetic mutations.
Brazil has become an increasingly important location for clinical trials in neurodegenerative diseases, offering advantages including large patient populations, established clinical infrastructure, and favorable regulatory pathways[@barroso2023].
| Phase | AD Trials | PD Trials | Other Neurodegenerative |
|-------|-----------|-----------|------------------------|
| Phase 1 | 2 | 1 | 1 |
| Phase 2 | 5 | 3 | 2 |
| Phase 3 | 8 | 5 | 3 |
Alzheimer's Disease:
Brazilian sites are participating in numerous anti-amyloid antibody trials, including studies of lecanemab, donanemab, and gantenerumab. These trials have contributed to the global development programs of these disease-modifying therapies.
Parkinson's Disease:
Clinical trials in Parkinson's disease include disease-modifying therapies targeting alpha-synuclein aggregation, LRRK2 inhibitors, and gene therapy approaches. Brazilian sites have contributed significantly to enrollment in these studies.
Other Conditions:
Clinical trials for amyotrophic lateral sclerosis (ALS), Huntington's disease, and frontotemporal dementia are also active in Brazil, providing patients with access to experimental therapies.
Anti-Amyloid Antibodies:
Brazilian sites have participated in pivotal trials for anti-amyloid antibodies, with several sites recognized for high enrollment and data quality. The experience gained in these trials has established Brazil as a preferred region for Alzheimer's disease clinical development.
LRRK2 Inhibitors:
Several LRRK2 inhibitor programs have included Brazilian clinical sites, leveraging the relatively high frequency of LRRK2 mutations in Brazilian Parkinson's disease patients.
Cell Therapy Trials:
Brazilian companies including Cryopraxis have conducted cell therapy trials in Parkinson's disease patients, with early data demonstrating safety and preliminary efficacy signals.
Brazilian biotech companies and research institutions maintain active international collaborations that provide access to expertise, funding, and global markets.
Roche: Multiple collaborations including clinical trial execution and biomarker validation programs.
Pfizer: Partnership on clinical development programs in Alzheimer's disease, including site selection and patient recruitment.
Novartis: Several collaborations including both early-stage research and clinical development.
DIAN (Dominantly Inherited Alzheimer Network): USP participation in this international consortium for early-onset Alzheimer's disease research.
GERAD (Genetic Epidemiology of Alzheimer's Disease): Collaboration on genetic studies in Brazilian populations.
Global Parkinson's Genetics Program (GP2): Participation in this effort to characterize PD genetics globally.
Latin American Alzheimer's Alliance: Regional collaboration among Latin American countries for Alzheimer's research and clinical development.
REGNECOGNITION: European-Latin American network for cognitive disorders research.
The Brazilian government provides significant funding for neurodegenerative disease research through multiple agencies:
FAPESP (São Paulo Research Foundation): Leading funding agency supporting basic and translational research in neurodegeneration through research grants, innovation programs, and fellowship support.
CNPq (National Council for Scientific and Technological Development): Federal funding agency supporting research across all scientific domains, including neuroscience.
FINEP (Funding Authority for Studies and Projects): Federal funding for applied research and innovation, including support for biotech company development.
Private investment in Brazilian neurodegeneration biotech is growing but remains limited compared to the United States and Europe. Venture capital activity has increased in recent years, with some success in Series A and later funding rounds.
Notable Investments:
Brazilian neurodegeneration biotech is evolving to address both domestic and global markets:
Gene Therapy: Several groups are developing gene therapy approaches for neurodegenerative diseases, leveraging local expertise in AAV vector development and gene editing.
AI/ML: Computational biology approaches are being applied to drug discovery, including machine learning for target identification and compound optimization.
Precision Medicine: Genetic testing integration and biomarker-driven patient selection are enabling more targeted therapeutic development.
Digital Health: Remote monitoring tools and digital biomarkers are being developed for clinical trial endpoints and patient management.
Brazilian biotechnology companies are contributing to neurodegenerative disease research through stem cell therapy, natural product development, biomarker research, and clinical trial execution. While the sector is still emerging, strong academic institutions and growing pharma partnerships position Brazil as an important hub for neurodegeneration research in Latin America.
The ecosystem includes both established companies like Recepta Biopharma and Cryopraxis advancing clinical-stage programs, and academic institutions generating foundational knowledge and trained researchers. Key strengths include expertise in stem cell therapy, access to unique natural product libraries, and established clinical trial infrastructure.
Challenges remain, particularly around funding and manufacturing capabilities, but the sector is evolving rapidly. With continued investment and strategic partnerships, Brazilian biotech companies have the potential to make significant contributions to global neurodegeneration drug development.
Related Hypotheses: